Showing 3481-3490 of 6631 results for "".
- Melanoma and Lung Cancer Drug May Also Treat Cutaneous Squamous Cell Carcinomahttps://practicaldermatology.com/news/melanoma-and-lung-cancer-drug-may-also-treat-cutaneous-squamous-cell-carcinoma/2462149/Plixorafenib, a new drug developed for treating melanoma and lung cancer, may also stop the progression of cutaneous squamous cell carcinoma, new research suggests. Researchers out of the University of Turku, Finland, discovered that plixorafenib (also called PLX8394) simultaneously inh
- Strength in Numbers: IPC, IFPA, and ILDS Presidents Sign Letter of Commitmenthttps://practicaldermatology.com/news/strength-in-numbers-ipc-ifpa-and-ilds-presidents-sign-letter-of-commitment/2462144/Hervé Bachelez, MD, PhD, President of the International Psoriasis Council (IPC), Hoseah Waweru, MD, President of the International Federation of Psoriasis Associations (IFPA), and Henry W. Lim MD, President of the International League of Dermatological Societies (ILDS) recently signed a le
- New Deadline: Allergan Aesthetics, University Lab Partners Launch Golden Passport Pitch Competition to Accelerate Aesthetics Start-Upshttps://practicaldermatology.com/news/news-you-can-use-allergan-aesthetics-university-lab-partners-launch-golden-passport-pitch-competition-to-accelerate-aesthetics-start-ups/2462091/University Lab Partners (ULP) and Allergan Aesthetics are launching the Golden Passport pitch competition for aesthetic startups. The Golden Passport provides the winner with a lab bench for one year and opportunities to engage with industry mentors including scientific and business lea
- European Commission Approves EBGLYSS (Lebrikizumab) for Moderate-to-severe ADhttps://practicaldermatology.com/news/european-commission-approves-ebglyss-lebrikizumab-for-moderate-to-severe-ad/2462141/The European Commission has approved EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy. Almirall will
- Ichthyosis Linked to Mood Disordershttps://practicaldermatology.com/news/ichthyosis-linked-to-mood-disorders/2462139/People living with Ichthyosis may be at higher risk for mental health conditions like depression and anxiety, according to a recent study in the Journal of the American Academy of Dermatology. Re
- Amorepacific Receives the CES Innovation Award for 'Lipcure Beam'https://practicaldermatology.com/news/amorepacific-receives-the-ces-innovation-award-for-lipcure-beam/2462138/Amorepacific's 'Lipcure Beam' technology received the Consumer Electronics Show 2024 (CES 2024) Innovation Award, marking the company's fifth consecutive win at the tech event. The 'Lipcure Beam' combines lip diagnosis, care, and makeup capabilities in one unit.
- Scientists 3D-print Hair Follicles in Lab-grown Skinhttps://practicaldermatology.com/news/scientists-3d-print-hair-follicles-in-lab-grown-skin/2462137/Scientists at Rensselaer Polytechnic Institute have 3D-printed hair follicles in human skin tissue cultured in the lab. This marks the first time that researchers have used the technology to generate hair follicles. The findings appear in
- Is Lower Extremity Lymphedema a Risk for Skin Cancer?https://practicaldermatology.com/news/is-lower-extremity-lymphedema-a-risk-for-skin-cancer/2462127/Patients with lymphedema may have twice the risk of developing basal cell carcinomas and squamous cell carcinomas on the lower extremities than their counterparts without lymphedema, according to a retrospective study published in the November 2023 issue of the Mayo Clinic Proceedings.&n
- In the Lab With Boston University Melanoma Researcher Deborah Langhttps://practicaldermatology.com/news/in-the-lab-with-boston-university-melanoma-researcher-deborah-lang-phd/2462120/Deborah Lang, PhD, associate professor of dermatology at Boston University Chobanian & Avedisian School of Medicine, received a two-year, $300,000 Discovery Boost Grant from the American Cancer Society (ACS) for her research project “Exploring roles for PAX3 in regulating gene expressio
- Study Validates Long-Term Safety of Delgocitinib Cream in Adults With Chronic Hand Eczemahttps://practicaldermatology.com/news/study-validates-long-term-safety-of-delgocitinib-cream-in-adults-chronic-hand-eczema/2462105/LEO Pharma’s Delgocitinib Cream was well-tolerated in adults with moderate to severe chronic hand eczema (CHE), according to results from the DELTA 3 Open-Label Extension Trial. What’s more, patients who entered the DELTA 3 trial after receiving delgocitinib cream